Research article

The influence of MMP-14, TIMP-2 and MMP-2 expression on breast cancer prognosis

Bernard Têtu1,2, Jacques Brisson3, Chang Shu Wang2, Hélène Lapointe2, Geneviève Beaudry2, Caty Blanchette3 and Dominique Trudel1

1Department of Pathology, Laval University, Québec, Canada
2Centre de Recherche en Cancérologie, Laval University, Québec, Canada
3Unité de Recherche en Santé des Populations, Laval University, Québec, Canada

Corresponding author: Bernard Têtu, bernard.tetu@chuq.qc.ca

Received: 3 Jun 2005 Revisions requested: 17 Aug 2005 Revisions received: 22 May 2006 Accepted: 23 May 2006 Published: 15 Jun 2006

Breast Cancer Research 2006, 8:R28 (doi:10.1186/bcr1503)
This article is online at: http://breast-cancer-research.com/content/8/3/R28
© 2006 Têtu et al.; licensee BioMed Central Ltd.
This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Introduction Matrix metalloproteinase (MMP)-2 is very active at degrading extracellular matrix. It is under the influence of an activator, membrane type 1 MMP (MMP-14), and the tissue inhibitor of metalloproteases (TIMP)-2. We hypothesized that the individual expression of these three markers or their balance may help to predict breast cancer prognosis.

Methods MMP-2, MMP-14 and TIMP-2 expression has been evaluated by 35S mRNA in situ hybridization on paraffin material of 539 breast cancers without distant metastasis at diagnosis and with a median follow-up of 9.2 years.

Results MMP-2 and MMP-14 mRNA was detected primarily in reactive stromal cells whereas TIMP-2 mRNA was expressed by both stromal and cancer cells. Of the three molecules, an adjusted Cox model revealed that high MMP-14 mRNA (≥ 10% cells) alone predicted a significantly shorter overall survival (p = 0.031) when adjusted for clinical factors (tumor size and number of involved lymph nodes). Prognostic significance was lost when further adjusted for Her-2/neu and urokinase-type plasminogen activator (p = 0.284). Furthermore, when all three components were analyzed together, the survival was worst for patients with high MMP-2/high MMP-14/low TIMP-2 (5 year survival = 60%) and best with low MMP-2/low MMP-14/high TIMP-2 (5 year survival = 74%), but the difference did not reach statistical significance (p = 0.328).

Conclusion Of the MMP-14/TIMP-2/MMP-2 complex, MMP-14 was the factor most significantly associated with the outcome of breast cancer and was an independent factor of poor overall survival when adjusted for clinical prognostic factors, but not for certain ancillary markers.

Introduction

In breast cancer, matrix metalloproteinase (MMP)-2 is a protease produced essentially by stromal cells. In vitro studies have clearly demonstrated that it degrades molecules that are abundant in the extracellular matrix (ECM) [1]. MMP-2 is also one of the major targets of recently developed synthetic MMP inhibitors [2,3]. However, recent literature demonstrates that the mechanism of action of MMP-2 is complex and that other molecules modulate its activity [4,5].

MMP-2 is secreted in an inactive pro-enzymatic form and, unlike other MMPs, its activity is modulated by tissue inhibitor of metalloproteases (TIMP)-2 [6] and the membrane type 1 MMP (MMP-14) [7]. Using zymography, breast cancers were found to express higher levels of activated MMP-2 than benign lesions [8,9] and in vitro studies showed that activated MMP-2 only is associated with an aggressive potential in breast cancer cell lines [10].

Animal studies showed that carcinoma cell lines transfected with MMP-14 produced higher levels of active MMP-2 and developed more lung metastases compared to parent tumor cells [11]. TIMP-2 inhibits most if not all activated MMPs and was shown to form a complex specifically with pro-MMP-2 [12]. However, the role of TIMP-2 is ambiguous since, in addition to its inhibitory effect, it is a main player in the MMP-2 pathway.
activation cascade [13]. However, clinical studies on breast cancer are rare, limited in size and do not address the potential interaction of all three factors (MMP-2, MMP-14 and TIMP-2).

This prompted us to test the hypothesis that the individual expression or the balance between MMP-2, MMP-14 and TIMP-2 expression may help to predict breast cancer prognosis.

Materials and methods

Population

The patients included in this study had node-positive or node-negative disease proven by histological examination of axillary lymph nodes, but with absence of distant metastases at diagnosis. The surgery for breast carcinoma was performed between 1 January 1980 and 31 December 1986. Clinical information was obtained from the patients’ charts by experienced research nurses. The tumor size, and number of examined and positive lymph nodes were obtained from the pathology reports. The histological types along with the historical and nuclear grades were reassessed by one of us (BT). The project has been approved by the Laval University Ethical Review board.

In situ hybridization

MMP-2, MMP-14 and TIMP-2 expression was analyzed by in situ hybridization. The technique used was a modification of the method of Wolf and colleagues [14] as described before [15]. S35 labeled antisense RNA probes were used. Plasmids were kindly provided by the late Prof. Paul Basset, IGIBM, Illkirch, France (MMP-2 and MMP-14) and the late Dr Anna Kossakowska, Calgary, Alberta (TIMP-2). cDNA inserts were prepared from breast cancer cDNA libraries, subcloned in pBluescript II (MMP-2 and MMP-14) and pBS KS- (TIMP-2) vectors and were used as templates for in vitro transcription to generate sense and anti-sense probes. The 2,124 base-pair (bp) MMP-2 cDNA was subcloned in the EcoRI site and extended from nucleotide 26 to 2,150; the 1,159 bp MMP-14 cDNA was subcloned in the EcoR1 site and extended from nucleotide 454 to 1,613; and the 210 bp TIMP-2 cDNA was subcloned in the HindIII/BamH1 site. Reduction of the probe length was achieved by partial alkaline hydrolysis. The quality of RNA preservation has been assessed with the use of antisense RNA probes for β-actin and negative controls were obtained with the use of sense probes. In situ hybridization for MMP-11 and urokinase-type plasminogen activator (uPA) were performed on all cases as previously described [15].

Immunohistochemistry

In addition to in situ hybridization, an immunohistochemical study was performed using the avidin-biotin complex (ABC) method as described before [15]. Studies were performed using primary antibodies to cathepsin D (Novocastra, Newcastle, UK; dilution, 1/200), p53 (Signet Labs, Dedham, MA, USA; ID labs, London, Ontario, Canada; dilution, 1/50), the heat-shock protein of 27 kDa (HSP-27, Hu27, Dr Jacques Landry, Hôtel-Dieu de Québec, Canada; dilution, 1/200), and HER-2/neu (Triton Biosciences, Alameda, CA, USA; dilution, 1/15). For each antibody, positivity was defined by the presence of at least 10% of cells expressing the marker. P53 expression was nuclear, HER-2/neu was membranous and HSP-27 was cytoplasmic.

Flow cytometry

DNA flow cytometric analysis was performed in all cases on formalin-fixed paraffin embedded tissues using the method described by Dressler and colleagues [16]. Ploidy and S-phase fraction were determined on single parameter histograms with the use of ModFit® (Verity Software House Inc., Topsham, ME, USA). Debris were excluded with the use of the 'Single Cut' algorithm. G0, G1 and G2 M were defined from a Gaussian curve while S-phase fraction was evaluated with the trapezoid model. All cases with a coefficient of variation exceeding 8% were excluded; the coefficient of variation averaged 6.1% (range 2.5% to 8.0%).

Hormone receptors

Estrogen and progesterone receptor measurement was obtained from the patient charts. In the early 1980s, analyses were performed using the hydroxylapatite method [17]. Positivity was defined by hormone levels above 10 fmol/mg proteins.

Interpretation

The light microscopic interpretation of in situ hybridization was done by two of us (BT, DT) without knowledge of the clinical information. The scoring was assessed separately on cancer and stromal cells using a semi-quantitative scale similar to that used for immunohistochemistry. For each cell compartment, the percentage of cancer or stromal cells expressing the marker (0%, <10%, 10% to 50%, >50%) was evaluated on the whole tumor surface of one representative section.

Statistical analysis

Distant-metastasis-free and overall survival (OS) curves were obtained for each protease according to Kaplan and Meier [18]. The difference between the curves was assessed using the log-rank test [19]. Correlation between protease expression and other recognized prognostic variables in breast cancer was determined by the Chi-square test [19]. Distant-metastasis-free and OS curves were generated using 10% as the cutoff point between those expressing low (negative) or high (positive) protease levels by stromal cells, as defined before [15,20]. The Cox proportional hazard model was used to evaluate the relationship between the expression of each protease, or a combination of more than one protease, and recurrence or death, adjusting for other known or suspected prognostic factors [21]. Hazard ratios for the occurrence of distant metastases or death of patients with any of the above...
combinations were obtained by univariate and multivariate analyses.

**Results**

In our tumor bank, information for MMP-2 was available from 610 breast cancers, from 544 for MMP-14 and from 549 cases for TIMP-2. Results for all three molecules were available from 539 cases and all analyses have been performed on this group of patients. The patients’ ages ranged from 29 to 72 years (average, 57.3). Of these patients, 190 (35.3%) were node-negative, 340 (63.1%) had node invasion, and the node status was unknown in 9 (1.6%). At last follow-up, 258 (47.9%) were alive and the follow-up of surviving patients ranged from 5.2 to 14.6 years (average, 9.5 years); 21 (3.9%) were lost to follow-up.

In this study, stromal cells expressed high MMP-2 (Figure 1a) in 263 (48.8%) cases, high MMP-14 (Figure 1b) in 164 (30.4%) cases and high TIMP-2 (Figure 1c) in 200 (37.1%) cases. Furthermore, high TIMP-2 expression by cancer cells (Figure 1d) was present in 225 (41.7%) cases while cancer cells expressed MMP-14 in 4 (0.7%) cases and none expressed MMP-2.

MMP-14 expression by stromal cells was significantly associated with a younger age, lymph node involvement, a ductal histology, HER-2/neu overexpression, and cathepsin D, MMP-11 (stromelysin-3) and uPA expression by stromal cells (Table 1). MMP-2 expression by stromal cells was associated with lymph node involvement, ductal histology, HER-2/neu and HSP-27 overexpression as well as cathepsin D, MMP-11 and uPA expression by stromal cells. TIMP-2 expression by stromal cells was associated with a ductal histology, and expression of HSP-27 and uPA. TIMP-2 expression by cancer cells was associated with peritumoral lymphovascular invasion, and expression of HSP-27, cathepsin D and uPA by stromal cells.

Figure 2 shows the OS curves for each of the three proteases. MMP-2 and MMP-14 expression by cancer cells was not evaluated because too few cases expressed those markers. No difference in OS was found between high and low MMP-2 and between high and low stromal and cancer TIMP-2 expression. However, high MMP-14 expression by stromal cells predicted a shorter survival ($p = 0.05$). In fact, the 5 year survival reached 72.2% for patients whose tumors had low MMP-14 levels as opposed to 64.6% for those with high MMP-14 levels. By multivariate analysis, using the Cox model adjusting for tumor size and number of involved lymph nodes, high MMP-14 expression was clearly a significant factor of poor survival (Table 2). The statistical significance was lost when HER-2/neu and uPA were included in the model. A trend was found for the association of MMP-14 expression and metastasis-free survival ($p = 0.08$). Indeed, the 5 year metastasis-free survival was 64.0% for patients with low MMP-14 as opposed to 54.3% for those with high MMP-14.

Figure 3 shows the overall survival curve considering the balance between MMP-2, MMP-14 and TIMP-2. Of the different combinations, OS was worst for those patients with high stromal MMP-2/high stromal MMP-14/low stromal TIMP-2 (60.3% survival at 5 years) and best with low stromal MMP-2/low stromal MMP-14/high stromal TIMP-2 (74.4% survival at 5 years).
### Table 1

**Association of high protease expression by stromal cells with other prognostic factors**

| Parameter                        | Cases | MMP-14 |  | MMP-2 |  | TIMP-2: stromal cells |  | TIMP-2: cancer cells |  |
|----------------------------------|-------|--------|---|-------|---|-----------------------|---|----------------------|---|
|                                  |       | Number | Percentage | p value | Number | Percentage | p value | Number | Percentage | p value |
| **Age years**                    |       |        |             |         |        |            |         |        |            |         |
| <50                              | 160   | 59     | 36.9        | 0.034   | 85     | 53.1       | 0.19    | 58     | 36.3       | 0.79    |
| ≥50                              | 379   | 105    | 27.7        | 0.034   | 178    | 47.0       | 0.19    | 142    | 37.5       | 0.14    |
| **Tumor size cm**                |       |        |             |         |        |            |         |        |            |         |
| <3                               | 297   | 93     | 31.3        | 0.98    | 146    | 49.2       | 0.65    | 118    | 39.7       | 0.14    |
| ≥3                               | 207   | 65     | 31.4        | 0.98    | 106    | 51.2       | 0.65    | 69     | 33.3       | 0.14    |
| **Involved lymph nodes**         |       |        |             |         |        |            |         |        |            |         |
| 0                                | 190   | 46     | 24.2        | 0.98    | 81     | 42.6       | 0.19    | 71     | 37.4       | 0.034   |
| 1 to 3                           | 166   | 61     | 36.7        | 0.98    | 93     | 56.0       | 0.041   | 69     | 41.6       | 0.29    |
| >3                               | 174   | 54     | 31.0        | 0.98    | 84     | 48.3       | 0.041   | 58     | 33.3       | 0.29    |
| **Peritumoral lymphovascular invasion** |       |        |             |         |        |            |         |        |            |         |
| Yes                              | 143   | 50     | 35.0        | 0.15    | 76     | 53.1       | 0.15    | 64     | 44.8       | 0.027   |
| No                               | 75    | 19     | 25.3        | 0.15    | 31     | 41.3       | 0.15    | 22     | 29.3       | 0.15    |
| **Histological grade**           |       |        |             |         |        |            |         |        |            |         |
| I                                | 54    | 18     | 33.3        | 0.98    | 25     | 46.3       | 0.98    | 19     | 35.2       | 0.98    |
| II                               | 277   | 81     | 29.2        | 0.98    | 133    | 48.0       | 0.98    | 109    | 39.4       | 0.98    |
| III                              | 197   | 64     | 32.5        | 0.98    | 99     | 50.3       | 0.98    | 69     | 35.0       | 0.98    |
| **Nuclear grade**                |       |        |             |         |        |            |         |        |            |         |
| I                                | 94    | 20     | 21.3        | 0.98    | 40     | 42.6       | 0.98    | 39     | 41.5       | 0.98    |
| II                               | 307   | 98     | 31.9        | 0.98    | 158    | 51.5       | 0.98    | 105    | 34.2       | 0.98    |
| III                              | 127   | 45     | 35.4        | 0.98    | 59     | 46.5       | 0.98    | 53     | 41.7       | 0.98    |
| **Histological type**            |       |        |             |         |        |            |         |        |            |         |
| Invasive ductal carcinoma        | 470   | 156    | 33.2        | 0.0006  | 238    | 50.6       | 0.021   | 164    | 34.9       | 0.003   |
| Others                           | 65    | 8      | 12.3        | 0.15    | 23     | 35.4       | 0.15    | 35     | 53.8       | 0.15    |
| **DNA ploidy**                   |       |        |             |         |        |            |         |        |            |         |
| Diploid                          | 143   | 37     | 25.9        | 0.09    | 64     | 44.8       | 0.09    | 58     | 40.6       | 0.09    |
| Non-diploid                      | 332   | 112    | 33.7        | 0.09    | 171    | 51.5       | 0.09    | 126    | 38.0       | 0.09    |
| **Estrogen receptors**           |       |        |             |         |        |            |         |        |            |         |
| Negative                         | 143   | 53     | 37.1        | 0.055   | 76     | 53.1       | 0.055   | 59     | 41.3       | 0.055   |
| Positive                         | 374   | 106    | 28.3        | 0.055   | 176    | 47.1       | 0.055   | 134    | 35.8       | 0.055   |
| **Progesterone receptors**       |       |        |             |         |        |            |         |        |            |         |
| Negative                         | 219   | 74     | 33.8        | 0.21    | 109    | 49.8       | 0.21    | 88     | 40.2       | 0.21    |
| Positive                         | 297   | 85     | 28.6        | 0.21    | 143    | 48.1       | 0.21    | 105    | 35.4       | 0.21    |
| **HER-2/neu expression**         |       |        |             |         |        |            |         |        |            |         |
| Negative                         | 437   | 121    | 27.7        | 0.0042  | 204    | 46.7       | 0.0042  | 158    | 36.2       | 0.0042  |
| Positive                         | 102   | 43     | 42.2        | 0.0042  | 59     | 57.8       | 0.0042  | 42     | 41.2       | 0.0042  |
| **p53**                          |       |        |             |         |        |            |         |        |            |         |

(All p values were calculated using Pearson's Chi² test, except where noted.)
This difference did not, however, reach significance ($p = 0.25$).

**Discussion**

This study confirms the complexity of the role of proteases on breast cancer prognosis. However, the prognostic influence of MMP-2 expression is not clear in the literature. Talvensaari-Mattila and colleagues [22], Sivula and colleagues [23] and Pacheco and colleagues [24] are among the few investigators who demonstrated a significant association between high MMP-2 mRNA or protein expression levels and a poor outcome. In our study of close to 600 cases, MMP-2 overexpression predicted a 15% greater risk of recurrence [15] but the association of MMP-2 expression with prognosis was not statistically significant. Other studies have failed to relate MMP-2 expression to a poorer prognosis [2,15,25]. These data are consistent with the complexity of the biology of MMP-2. In our study, they may also be explained in part by the fact that in situ hybridization cannot differentiate between the active and inactive forms.

In our study, when each factor was taken separately, and after adjustment for clinical prognostic factors, only MMP-14 was a significant factor of survival, suggesting that MMP-14 may be one of the key steps in tumor invasion and metastasis. However, the prognostic significance of MMP-14 was not independent of HER-2/neu and uPA. This finding can be explained by the strong regulatory interaction between HER-2/neu, uPA and MMPs [26]. Indeed, HER-2/neu was found to induce uPA expression and to directly up-regulate MMP expression via transcription factor-binding sites [26].

However, the association of MMP-14 but not MMP-2 expression with survival may be explained by the fact that MMP-14 has many substrates other than MMP-2. Indeed, in vitro and clinical studies support the major role played by MMP-14 on ECM remodeling. MMP-14 acts either directly by degrading ECM components such as type III collagen or indirectly by activating pro-MMP-2 and also by inducing highly vascularized tumors through vascular endothelial growth factor (VEGF) up-regulation [27-30]. MMP-14 also induces functional activation of the integrin $\alpha V\beta 3$, which binds to MMP-2 and increases vitronectin-mediated adhesion and migration of MCF7 cells [31]. Among prior clinical studies, high MMP-14 mRNA expression was an independent factor of both tumor invasion and lymph node metastasis in carcinoma of stomach [32], lung [33] and cervix [34]. In breast cancer, highest expression of MMP-14 by...
Figure 2

Overall survival for matrix metalloproteinase (MMP)-2, MMP-14 and tissue inhibitor of metalloproteases (TIMP)-2 expression by stromal and cancer cells. Overall survival curves for: (a) matrix metalloproteinase (MMP)-2 expressed by stromal cells; (b) MMP-14 expressed by stromal cells; (c) tissue inhibitor of metalloproteases (TIMP)-2 expressed by stromal cells; and (d) TIMP-2 expressed by cancer cells (p values obtained by the log-rank test).

Table 2

Hazard ratios for MMP-14, MMP-2, TIMP-2 and combination of MMP-14 MMP-2 TIMP-2 on breast cancer overall survival

|                  | Univariate |            |          | Multivariate |            |          | Multivariate |            |          |
|------------------|------------|------------|----------|--------------|------------|----------|--------------|------------|----------|
|                  | HR        | 95% CI     | p value  | HR           | 95% CI     | p value  | HR           | 95% CI     | p value  |
| MMP-14           | 1.31      | 0.99–1.72  | 0.05     | 1.36         | 1.03–1.81  | 0.031    | 1.18         | 0.87–1.59  | 0.28     |
| MMP-2            | 1.14      | 0.88–1.47  | 0.33     | 1.14         | 0.87–1.49  | 0.34     | 0.98         | 0.73–1.31  | 0.87     |
| TIMP-2: stromal cells | 0.91 | 0.69–1.19 | 0.51     | 1.04         | 0.78–1.38  | 0.79     | 0.89         | 0.66–1.19  | 0.43     |
| TIMP-2: cancer cells | 1.07 | 0.83–1.39 | 0.61     | 1.09         | 0.83–1.43  | 0.53     | 1.02         | 0.77–1.34  | 0.91     |
| MMP-14+/MMP-2-/TIMP-2- | 1.0 |        |          | 1.0         |            |          |              |            |          |
| MMP-14+/MMP-2+/TIMP-2+ | 1.46 | 0.89–2.38 | 0.13     | 1.29         | 0.77–2.16  | 0.33     |              |            |          |
| Other categories | 1.11      | 0.76–1.63  | 0.59     | 1.03         | 0.68–1.55  | 0.90     |              |            |          |

*aCox model adjusting for tumor size and number of involved lymph nodes. bCox model adjusting for tumor size, number of involved lymph nodes, HER-2/neu and urokinase plasminogen activator. cTIMP-2 by stromal cells. CI, confidence interval; HR, hazard ratio; MMP, matrix metalloproteinase; TIMP, tissue inhibitor of metalloproteases. 
RT-PCR was found in cases with lymph node metastases [35,36], poor clinical stage and larger tumor size [36].

In our study, MMP-14 mRNA was located in reactive stromal cells close to cancer cells. This is consistent with data from the literature [37] that identified MMP-14 mRNA within myofibroblasts [38]. However, the location of MMP-14 in breast tissue is debated and others found MMP-14 mRNA in cancer cells [39]. Using immunohistochemistry, MMP-14 was located within either stromal and/or cancer cells [40-43].

In our study, TIMP-2 did not provide independent prognostic information. In the literature on breast cancer, the role of TIMP-2 was controversial. This may explain contradictory results in which patients with higher TIMP-2 expression either experienced low cancer recurrence/progression [44,45] or a poor prognosis [25,46-49], emphasizing the overall activating or inhibitory role of TIMP-2. These contradictory findings may be explained by the versatile role of TIMP-2 [12]. Indeed, TIMP-2 increases growth rates of murine, bovine and human cells [50], but also inhibits tumor growth and angiogenesis in melanoma B16F10 cells [51], attenuates migration of MDA-MB23 breast cancer cells through a bone marrow fibroblast monolayer [52] and abolishes the tumor-promoting effect of fibroblasts on MCF7 cells injected with matrigel in nude mice [53].

The relationship of survival with the combination of MMP-2, MMP-14 and TIMP-2, although not statistically significant, showed that survival was worse for those patients with high MMP-2/high MMP-14/low TIMP-2 and best with low MMP-2/low MMP-14/high TIMP-2. This lack of statistical significance may be explained by the sample size, which may be too small to reach significance, or by the versatile role of TIMP-2, which may be either a favorable or an unfavorable factor. Different combinations of proteases and protease inhibitors or activators have been investigated in the literature but clinical studies are limited and involve few patients. Clinical studies suggest that TIMP-2, or the ratio of MMP-2 and TIMP-2 expression, may play a critical role on cancer progression. For example, higher MMP-2/TIMP-2 ratios were associated with recurrences in patients with bladder [54] or uterine cervix [55] cancer. In a study on 14 patients, Onisto and colleagues [56] report that a high MMP-2/TIMP-2 ratio correlated with lymph node metastases in breast cancer while it predicted a better outcome in another study [25].

Conclusion
Our data show that, of the three proteases studied, MMP-14 was most strongly associated with breast cancer prognosis but was not independent of HER-2/neu or uPA, which may limit its usefulness as a prognostic marker. When all three proteases are studied in combination, a tendency was found for tumors with high MMP-2, high MMP-14 and low TIMP-2 expression to predict a poor prognosis but the results did not reach significance.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
BT, JB, CSW, and DT participated in the design of the study. CSW, HL and GB developed and prepared all in situ hybridization analyses. BT and DT interpreted all in situ hybridization slides. JB supervised the statistical analysis, which was carried out by CB. All authors participated to the discussion on the significance of the results, the drafting of the manuscript and approved the final version.

Acknowledgements
Sources of support: project supported by the Cancer Research Society Inc. Data base has been raised through a grant from the National Cancer Institute of Canada with funds from the Canadian Cancer Society, the Canadian Breast Cancer Foundation and a joint program from the 'Fonds de la Recherche en Santé du Québec’ and Hydro-Québec. Dr Têtu was recipient of a research clinical scholarship of the 'Fonds de la Recherche en Santé du Québec’ when he completed this project.

References
1. Visse R, Nagase H: Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003, 92:827-839.
2. Brown PD, Giavazzi R: Matrix metalloproteinase inhibition: a review of anti-tumour activity. Ann Oncol 1995, 6:967-974.
3. Vihtonen P, Kahari VM: Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. Int J Cancer 2002, 99:157-166.
4. Sternlicht MD, Werb Z: How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 2001, 17:463-516.
5. Bigg HF, Morrison CJ, Butler GS, Bogoyevitch MA, Wang Z, Solo- way PD, Overall CM: Tissue inhibitor of metalloproteinases-4 inhibits but does not support the activation of gelatinase A via efficient inhibition of membrane type 1-matrix metalloproteinase. Cancer Res 2001, 61:3610-3618.
6. Stetler-Stevenson WG, Brown PD, Onisto M, Levy AT, Liotta LA: Tissue inhibitor of metalloproteinases-2 (TIMP-2) mRNA

Available online http://breast-cancer-research.com/content/8/3/R28
expression in tumor cell lines and human tumor tissues. *J Biol Chem* 1990, 265:19393-19398.

7. Deruginia EL, Rathouz B, Morosov E, Postnovna TI, DiSciopio R, Smith JW, Strongin AY: MT1-MMP initiates activation of pro-MMP-2 and integrin alphavbeta3 promotes maturation of MMP-2 in breast carcinoma cells. *Exp Cell Res* 2001, 263:209-223.

8. Lee KS, Rha SY, Kim SJ, Kim JH, Roh JK, Kim BS, Chung HC: Sequential activation and production of matrix metalloproteinase-2 during breast cancer progression. *Clin Exp Metastasis* 1996, 14:512-519.

9. Raucci AG, Noel A, Duggan C, McDermott E, O'Higgins N, Pinto J, Basset P, Foidart JM, Duffy MJ: Assay of matrix metalloproteinases types 1, 2 and 3 in breast cancer. *Br J Cancer* 1997, 78:926-931.

10. Azzam HS, Arand G, Lippman ME, Thompson EW: The association of cyclooxygenase types 1, 2, and 3 expression in tumor cell lines and human tumor tissues. *Cancer Res* 1996, 56:5678-5683.

11. Bader AH, Edwards DR, Murphy G: Metalloproteinase inhibitors: biological actions and therapeutic opportunities. *J Cell Sci* 2002, 115:3719-3727.

12. Banhegrew-Brun C, Coison CM, Chojum N, Nerlich AG: Matrix metalloproteinases in cancer: comparison of known and novel aspects of their inhibition as a therapeutic approach. *Expert Rev Anticancer Ther* 2005, 5:149-163.

13. Wolf C, Rouyer N, Lutz Y, Adda C, Lorioit M, Belloq JP, Chambon P, Basset P: Stromelysin-3 belongs to a subgroup of proteinases expressed in breast carcinoma fibroblastic cells and possibly implicated in tumor progression. *Hum Pathol* 1998, 29:979-985.

14. Pressler LG, Bartow SA: DNA flow cytometry in solid tumors: practical aspects and clinical applications. *Semin Diagn Pathol* 1999, 16:65-82.

15. Erdos T, Best-Belpomme M, Bessada R: A rapid assay for binding estradiol to uterine receptor(s). *Anal Biochem* 1970, 37:244-252.

16. Kaplan EL, Meier P: Non-parametric estimation from incom- plete observations. *J Am Stat Assoc* 1958, 53:453-481.

17. Armitage P: Statistical Methods in Medical Research. New York: John Wiley & Sons; 1991.

18. Taylor AM, Gatenby PA, Chesson NE, Vane JR: Limited metastatic spread in mice is associated with a reduced number of myeloid cells in the lung. *Exp Cell Res* 2010, 316:632-640.

19. Balk RA, Wang, L., Bandyopadhyay, D., Schipani, E., Vincent, K., Solomon, D., Dlin, D., Simons, A., Hahn, S., Papadopoulos, N., and Dhillon, A.: Expression of MMP-2 and TIMP-2 in the breast cancer microenvironment: a multidimensional approach. *Breast Cancer Res Treat* 2006, 98:315-322.
imbalance in hepatocellular carcinoma. *Int J Cancer* 2002, 97:425-431.

46. Visscher DW, Hoyhtya H, Ottosen SK, Liang CM, Sarkar FH, Crissman JD, Friedman R: Enhanced expression of tissue inhibitor of metalloproteinase-2 (TIMP-2) in the stroma of breast carcinomas correlates with tumor recurrence. *Int J Cancer* 1994, 59:339-344.

47. Ruckkolainen H, Paakk T, Turpeenniemi-Hujanen T: Tissue and circulating immunoreactive protein for MMP-2 and TIMP-2 in head and neck squamous cell carcinoma – tissue immunoreactivity predicts aggressive clinical course. *Mod Pathol* 2006, 19:208-217.

48. Katayama A, Bando N, Kishibe K, Takahara M, Ogino T, Nonaka S, Harabuchi Y: Expressions of matrix metalloproteinases in early-stage oral squamous cell carcinoma as predictive indicators for tumor metastases and prognosis. *Clin Cancer Res* 2004, 10:834-840.

49. Ross JS, Kaur P, Sheehan CE, Fisher HA, Kaufman RA Jr, Kallakury BV: Prognostic significance of matrix metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expression in prostate cancer. *Mod Pathol* 2003, 16:198-205.

50. Hayakawa T, Yamashita K, Ohuchi E, Shinagawa A: Cell growth-promoting activity of tissue inhibitor of metalloproteinases-2 (TIMP-2). *J Cell Sci* 1994, 107:2373-2379.

51. Valente P, Fassina G, Melchiori A, Masiello L, Cilli M, Vacca A, Onisto M, Santi L, Stetler-Stevenson WG, Albini A: TIMP-2 over-expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis. *Int J Cancer* 1998, 75:246-253.

52. Saad S, Bendall JJ, James A, Gottlieb DJ, Bradstock KF: Induction of matrix metalloproteinases MMP-1 and MMP-2 by co-culture of breast cancer cells and bone marrow fibroblasts. *Breast Cancer Res Treat* 2000, 63:105-115.

53. Noel AC, Hajitou A, LHoir C, Maquoi E, Baramova E, Lewalle JM, Remacle AG, Kevers F, Brown P, Calberg-Bacq CM, Foidart JM: Inhibition of stromal matrix metalloproteases: effects on breast-tumor promotion by fibroblasts. *Int J Cancer* 1998, 76:267-273.

54. Gohji K, Fujimoto N, Fuji A, Komiyama T, Okawa J, Nakajima M: Prognostic significance of circulating matrix metalloproteinase-2 to tissue inhibitor of metalloproteinases-2 ratio in recurrence of urothelial cancer after complete resection. *Cancer Res* 1996, 56:3196-3198.

55. Nuovo GL, MacConnell PB, Simair A, Valea F, French DL: Correlation of the in situ detection of polymerase chain reaction-amplified metalloproteinase complementary DNAs and their inhibitors with prognosis in cervical carcinoma. *Cancer Res* 1995, 55:267-275.

56. Onisto M, Riccio MP, Scannapieco P, Caeannazo C, Griggio L, Spina M, Stetler-Stevenson WG, Garbisa S: Gelatinase A/TIMP-2 imbalance in lymph-node-positive breast carcinomas, as measured by RT-PCR. *Int J Cancer* 1995, 63:621-626.